TP53 and myelodysplastic syndrome: The WHO 2022 diagnostic criteria reclassified MDS into three groups: myelodysplastic tumors with type 1/2 of primitive cell proliferation(MDS-IB1/IB2, 222 cases), MDS with fibrosis(MDS-f, 41 cases), and MDS with biallelic TP53 mutation(MDS-biTP53, 19 cases).